Enclomiphene (also known as Androxal) is a non-steroidal, oral selective estrogen receptor modulator (SERM) that has been studied as a potential treatment for male infertility. It is a derivative of clomiphene, a drug that has been used for decades to treat female infertility.

Enclomiphene works by binding to the estrogen receptors in the hypothalamus and pituitary gland, which play a key role in regulating the production of gonadotropins, the hormones that stimulate the production of testosterone in the testes. By binding to these receptors, enclomiphene can help to increase the production of testosterone in men with low testosterone levels, a condition known as hypogonadism.

In clinical trials, enclomiphene has been found to be effective in increasing testosterone levels in men with hypogonadism. For example, one study found that men with low testosterone levels who were treated with enclomiphene for 12 weeks experienced a significant increase in testosterone levels, compared to those who received a placebo. Additionally, the men who received enclomiphene also had improvements in sperm count, sperm motility, and sperm morphology.

Enclomiphene is also being studied as a potential treatment for a condition known as secondary hypogonadism, which is characterized by a deficiency in gonadotropins, the hormones that stimulate the production of testosterone in the testes. Secondary hypogonadism can be caused by a variety of factors, including obesity, diabetes, and certain medications.

In addition to its potential benefits for male fertility, enclomiphene may also have other potential therapeutic uses. For example, it is being studied as a potential treatment for bone loss in men with low testosterone levels. Additionally, it has been suggested that enclomiphene may have potential anti-cancer properties, although more research is needed to confirm this.

While enclomiphene has been found to be effective in increasing testosterone levels in men with hypogonadism and improving sperm quality, more research is needed to fully understand its mechanism of action and determine its long-term safety and efficacy. Additionally, it is important to note that enclomiphene has not been approved by the FDA for the treatment of male infertility or any other indication, and its safety and efficacy in these populations have not been established.

In conclusion, enclomiphene (Androxal) is a non-steroidal, oral selective estrogen receptor modulator (SERM) that is being studied as a potential treatment for male infertility, particularly hypogonadism and secondary hypogonadism. It works by binding to the estrogen receptors in the hypothalamus and pituitary gland, thereby increasing the production of testosterone. Enclomiphene has shown promising results in clinical trials, however more research is needed to fully understand its mechanism of action, safety and long-term efficacy. Additionally, it is important to note that enclomiphene has not yet been approved by the FDA for any indication and should not be used without a prescription and close medical supervision.